# US 2004/0001864 A1 · Vaccine against foot-and-mouth disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001864 A1
- Document ID: US20040001864A1
- Status: Published application
- Kind: A1
- Application number: 10/327,481
- Filed: 2002-12-20
- Published: 2004-01-01
- Earliest claimed: 2000-06-29
- Assignees: Merial Limited
- Inventors: Andrew Maurice Quatermain King; Alison Jane Burman; Jean-Christophe Francis Audonnet; Michel Francois Antoine Lombard
- Web page: https://patentgrep.com/patent/US20040001864A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/135: Foot- and mouth-disease virus
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2770/32122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/32134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A vaccine against foot-and-mouth disease, using as antigen an efficient amount of empty capsids of the foot-and-mouth virus. The empty capsids are obtained by expressing, in eukaryotic cells, cDNA of the P1 region of the foot-and-mouth virus genome coding for the capsid and cDNA of the region of the foot-and-mouth virus genome coding for protease 3C. The vaccine further includes a carrier or excipient pharmaceutically acceptable in veterinary medicine.

## Claims

### Claim 1

A vaccine or immunogenic composition against foot-and-mouth virus comprising a pharmaceutically or veterinarily acceptable carrier or excipient, and, as an antigen, empty capsid of foot-and-mouth virus, present in an amount effective to elicit an immunological or protective response against foot-and-mouth virus, wherein the capsid is the expression product, in a eukaryotic cell, of cDNA encoding the P1 region and cDNA encoding the 3C protease, of the foot-and-mouth virus genome.

### Claim 2 (depends on 1)

The vaccine or immunogenic composition according to claim 1, wherein the cDNA coding for P1 also codes for all or part of 2A.

### Claim 3 (depends on 1)

The vaccine or immunogenic composition according to claim 1, wherein the cDNA coding for 3C also codes for all or part of the proteins 3B.

### Claim 4 (depends on 1)

The vaccine or immunogenic composition according to claim 1, wherein the empty capsids are present in the vaccine as sub-units, in a sufficient amount.

### Claim 5 (depends on 4)

The vaccine or immunogenic composition according to claim 4, wherein the empty capsids in the form of sub-units are obtained by expression of the cDNA in eukaryotic cells, by an expression vector in vitro, under the control of an inducible promoter or a late promoter of viral origin.

### Claim 6 (depends on 4)

The vaccine or immunogenic composition according to claim 4, wherein the promoter is selected from among T7 bacteriophage promoter, heat-shock promoter or a late promoter of viral origin.

### Claim 7 (depends on 5)

The vaccine or immunogenic composition according to claim 5, wherein the promoter is the T7 bacteriophage promoter and the empty capsids in the form of sub-units are obtained by expression of the cDNA in the presence of the expression of T7 polymerase.

### Claim 8 (depends on 5)

The vaccine or immunogenic composition according to claim 5, wherein the expression vectors are selected from among the viral vectors, preferably the poxviruses, notably the vaccinia virus, and the plasmid vectors, or the expression cassette is integrated in the eukaryotic cells.

### Claim 9 (depends on 8)

The vaccine or immunogenic composition according to claim 8, wherein the vector is a pox virus and the late promoter of viral origin is selected from among P11K of the vaccinia virus, P28K of the vaccinia virus and P160K ATI of the cowpox virus.

### Claim 10 (depends on 4)

The vaccine or immunogenic composition according to claim 4, wherein the eukayotic cells are from a cell line, preferably BHK-21, CHO, COS RK13, Vero, MDBK or PK15 cells.

### Claim 11 (depends on 4)

The vaccine or immunogenic composition according to claim 4, wherein it is formulated with a medium for preserving the empty capsids, notably of the DMEM type.

### Claim 12 (depends on 4)

The vaccine or immunogenic composition according to claim 4, wherein it contains an adjuvant.

### Claim 13 (depends on 12)

The vaccine or immunogenic composition according to claim 12, wherein it contains an adjuvant aluminum hydroxide, saponine, avridine, DDA, a polymer of acrylic or methacrylic acid, a polymer of maleic anhydride and an alkenyl derivative, GM-CSF, or in that it is formulated in the form of a water-in-oil, oil-in-water or water-in-oil-in-water emulsion.

### Claim 14 (depends on 1)

The vaccine or immunogenic composition according to claim 1, wherein it comprises an expression vector containing cDNA so as to produce the capsids in vivo.

### Claim 15 (depends on 14)

The vaccine or immunogenic composition according to claim 14, wherein the vector is viral vector or a plasmid vector.

### Claim 16 (depends on 15)

The vaccine or immunogenic composition according to claim 15, wherein the viral vector is selected from among poxviruses, notable vaccinia virus, avipox such as fowipox and canarypox, racoonpox swinepox, capripox; adenovirus and herpesvirus.

### Claim 17 (depends on 14)

The vaccine or immunogenic composition according to claim 14, wherein the cDNA is expressed by a viral vector under the control of a late promoter of viral origin.

### Claim 18 (depends on 17)

The vaccine or immunogenic composition according to claim 17, wherein the vector is a poxvirus and the late promoter of viral origin is selected from among P11 K of the vaccinia virus, P28K of the vaccinia and P160K ATI of the cowpox virus.

### Claim 19 (depends on 17)

The vaccine or immunogenic composition according to claim 17, wherein the cDNA is expressed by a plasmid vector, under the control of a strong early promoter of viral origin or of cellular origin, preferably the early promoter of the cytomegalovirus CMV-IE.

### Claim 20 (depends on 19)

The vaccine or immunogenic composition according to claim 19, wherein the cDNA is expressed by a plasmid vector, under the control of a promoter selected from among the early or late promoter of the SV40 virus, the LTR promoter of the Rous sarcoma virus, the promoter of a gene of the cytoskeleton such as the desmine promoter or the actin promoter.

### Claim 21 (depends on 14)

The vaccine or immunogenic composition according to claim 14, wherein the vaccine is formulated with a 9 parts per 1000 NaCI saline solution or a phosphate buffer.

### Claim 22 (depends on 14)

The vaccine or immunogenic composition according to claim 14, wherein the vaccine contains and adjuvant.

### Claim 23 (depends on 22)

The vaccine or immunogenic composition according to claim 22, wherein the vaccine contains a vector viral and the adjuvant contains a cationic lipid containing a quaternary ammonium salt, or formula
R1OCH2CH(OR1)CH2N+(CH3)2(R2)X
wherein R1 is a linear, saturated or unsaturated aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X denotes a hydroxyl or amine group.

### Claim 24 (depends on 13)

The vaccine or immunogenic composition according to claim 13, wherein the adjuvant contains DMRIE, preferably combined with a neutral lipid, notably DOPE, to form DMRIE-DOPE.

### Claim 25 (depends on 22)

The vaccine or immunogenic composition according to claim 22, wherein the vaccine contains a plasmid vector and the adjuvant contains a polymer of acrylic or methacrylic acid, or a polymer of maleic anhydride and an alkenyl derivative.

### Claim 26 (depends on 13)

The vaccine or immunogenic composition according to claim 13, wherein the adjuvant contains carboner.

### Claim 27 (depends on 22)

The vaccine or immunogenic composition according to claim 22, wherein the adjuvant contains GM-CSF.

### Claim 28 (depends on 22)

The vaccine or immunogenic composition according to claim 22, wherein it contains a vector which expresses GM-CSF in vivo.

### Claim 29 (depends on 1)

The vaccine or immunogenic composition according to claim 1, wherein the empty capsids are heat-stabilized.

### Claim 30 (depends on 29)

The vaccine or immunogenic composition according to claim 29, wherein the empty capsids contain unnatural disulphide bridges.

### Claim 31 (depends on 29)

The vaccine or immunogenic composition according to claim 29, wherein the cDNA contains the sequence coding for VP2, VP0 or P1, modified by the incorporation of a codon coding for a cysteine.

### Claim 32 (depends on 31)

The vaccine or immunogenic composition according to claim 31, wherein the codon coding for the amino acid 179 is replaced by a codon coding for a cysteine.

### Claim 33 (depends on 23)

The vaccine or immunogenic composition according to claim 23, wherein the adjuvant contains carbon.
